The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Calithera Biosciences; Daiichi Sankyo/Lilly; EMD Serono; Genentech; Janssen Oncology; Lilly; Merck KGaA; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Mary Weber Redman
Consulting or Advisory Role - AstraZeneca
 
Konstantin H. Dragnev
Research Funding - G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
Liza C. Villaruz
Consulting or Advisory Role - Achilles Therapeutics; Daiichi Sankyo/Astra Zeneca; Takeda
Research Funding - AstraZeneca (Inst); BMS (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst); Regeneron (Inst)
 
Bryan A. Faller
Consulting or Advisory Role - LEK
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; EB SQUIBB; Eisai; Genentech; Lilly; Merck; Novartis; Takeda
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Array BioPharma; AstraZeneca; Biogin; Bristol-Myers Squibb; Celgene; Epizyme; HERON; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; Sunesis Pharmaceuticals; TRACON Pharma
Honoraria - Cardinal Health
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Kite, a Gilead company; MorphoSys
Travel, Accommodations, Expenses - Abbvie/Genentech; Bristol-Myers Squibb; Cardinal Health
 
Susan Hines
No Relationships to Disclose
 
Lu Qian
No Relationships to Disclose
 
Katherine Minichiello
No Relationships to Disclose
 
David R. Gandara
Honoraria - AstraZeneca; CBPartners; MJH Life Sciences
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly (Inst); Merck; OncoCyte (Inst); Roche/Genentech
Research Funding - Amgen (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb?; Candel Therapeutics; Cybrexa Therapeutics; eFFECTOR Therapeutics; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; I-Mab; Immunocore; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Oncternal Therapeutics; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Karen Kelly
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sanko; Debiopharm Group; EMD Serono; EMD Serono; Genentech; Genmab; GlaxoSmithKline; Inivata; Janssen; Lilly; Novartis; Novartis; Regeneron; Symphogen; Takeda; Targeted Oncology
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Regeneron